Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?
Smith
Stephen D
SD
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. smiths11@ccf.org
Sweetenham
John W
JW
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000951:Antigens, Neoplasm / Q000096:biosynthesis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D045744:Cell Line, Tumor; D002986:Clinical Trials as Topic; D005500:Follow-Up Studies; D006801:Humans; D019394:Ki-67 Antigen / Q000096:biosynthesis; D020522:Lymphoma, Mantle-Cell / Q000628:therapy*; D008495:Medical Oncology / Q000379:methods*; D008875:Middle Aged; D000069283:Rituximab; D013997:Time Factors; D014178:Translocation, Genetic; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000951:Antigens, Neoplasm; D019394:Ki-67 Antigen; D000069283:Rituximab